Kenvue Inc. (KVUE)

Investment Committee Summary

Investment Thesis

At $19.43 on 25 August 2026, near 17x forward earnings, the market prices Kenvue as an average consumer-health franchise: dependable dividend, low-single-digit organic growth, no re-rating. The engine broadly agrees rather than dissents, but marks the price down. Triangulated fair value is $16.06, -17% against spot, so the shares are trading rich to the blended evidence, with a probability-weighted value of $17.98 and a 12-month target of $18.40; the rating is HOLD. Two features the headline multiple hides do the work. First, the tree puts close to two-fifths of its weight on structural or recessionary paths, in which private-label share gains compress organic growth and gross margin together rather than one at a time. Second, the independent capital-spending-bridge discounted cash flow lands well beneath the market price, flagging that the current rating already assumes steady execution rather than paying for it once delivered. Base-case earnings power on a segment operating margin near 18% supports the mid-cycle target only if pricing holds and the beauty portfolio recovers, and net debt of ~$7.6B against a covered but tightly financed dividend leaves little slack. The single most damaging risk is durable private-label substitution in the core over-the-counter and skin-care lines, eroding volume and pricing at once and validating the structural path below the 52-week low.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($19.43) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear mechanism is not a crash but slow structural erosion. Kenvue's brands compete against retailer private label in categories where the value gap has narrowed and shoppers have grown willing to trade down. If organic growth drifts toward zero while input and promotional costs keep gross margin under pressure, the mid-cycle earnings the base case needs never materialise. The market then re-rates a low-growth, levered staples name well beneath the 17x it pays today, and the operating margin near 18% gives ground as promotion replaces pricing. With net debt of ~$7.6B and a dividend that already absorbs most free cash flow, there is little room to defend the payout through a downturn without borrowing to do it. Earnings and the multiple compress together, and the structural path settles below the 52-week low.

Key Debate

P/E Multiple explains 54% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

What the Market Is Pricing In

At the current price, the market pays 16.5× consensus forward EPS, vs the house DCF terminal 14.0×, and a peer median 19.0×. The house DCF sits 25% below spot, so the market is pricing in more than the house case — roughly 2.2pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily multiple-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Private-Label / Brand Erosion' downside ($7.60) to a 'Bull — Defensive Re-Rate' bull case ($29.10); the probability-weighted blend (PWEV $17.98) is -7% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 0.9% of revenue; free cash flow net of SBC is $1.59B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Private-Label / Brand Erosion (20%, $7.60). Structural impairment — private-label / brand erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Consumer / Input Recession (18%, $14.40). Cyclical downturn — branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) weakens for 1–2 years before normalising.
• Base — Pricing-Led Organic Growth (34%, $19.60). Mid-cycle — normalised branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail); disciplined capital allocation; steady returns.
• Growth — Premium Innovation + EM (20%, $24.40). Upside — premium innovation + emerging markets lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Defensive Re-Rate (8%, $29.10). Upside tail — sustained tight conditions or a structural re-rate on premium innovation + emerging markets.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Rating vs blend — the key debate. The rating tracks the multiple-discipline fair value (Monte Carlo $16.37 + scenario PWEV $17.98, ≈ spot); the weighted blend $16.06 (-17%) sits below it because the cash-flow DCF ($14.55) is materially more conservative than the market multiple. Whether the current multiple is justified is the central question for this name — and the principal downside risk to the rating.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $16.37 and 34% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (54% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 7.5%, 14.0x terminal FCF multiple → $14.55. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $7.90; the peer-median forward P/E is 19.0x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 62% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Household & Personal Care multiple (AI re-rating) (base 16.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 18.4× (simple median 19.0×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $13.47–$21.85, centre $17.20 (-12% vs spot); spot sits at the 71st percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Defensive Re-Rate): $29.10.

Company Overview & Business Model

Kenvue Inc. — CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS. Kenvue Inc. is a consumer health company globally.

How it makes money.

Edge. Narrow moat — Kenvue's moat is narrow — market-leading consumer-health brands (Tylenol, Listerine, Neutrogena, Band-Aid) carry real equity and shelf position, but many categories face capable private label and the brands were carved out of J&J without the parent's distribution muscle; a narrow moat supports roughly the staples average (~17x forward, where it trades), and if private-label erosion accelerates or the Tylenol litigation overhang deepens, the terminal multiple should compress toward the low-teens rather than re-rate to premium-staples levels.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 150% — cash-backed.

Competitive Moat

Moat sources:

• Portfolio of category-leading OTC/self-care brands with decades of trust (brand-trust moat)
• Retail shelf position and pharmacy distribution inherited from J&J
• Scale in OTC regulatory approvals and clinical brand claims
• Limited pricing power vs premium staples — offset by private-label competition

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2025Q2): management +0.29 vs analyst floor +0.09 → delta +0.21 (n=12 mgmt / 7 Q&A; 11th pctile across the S&P book, z -1.3).

Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).

News (last 365d, 1302 articles): avg ticker sentiment +0.12 (bullish 14% / bearish 5%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2027-03-15 (~203d) — Skin Health & Beauty (Neutrogena/Aveeno) turnaround progress checkpoint (authored)

Forecast Track Record

• EPS surprise: beat 75% of the last 8 quarters; average surprise +7.7%.
• Prior-forecast backtest (12 snapshots, 2026-06-26→2026-08-20): directional hit-rate 33%; mean predicted -4.3% vs realised +1.0%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

4 catalysts in the next 90 days (of 13 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic sales growth < 0.01 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Adjusted gross margin < 0.585 (2 consecutive prints). Sustained gross-margin erosion below the high-50s would indicate pricing power is failing to cover input and promotional costs, consistent with the mid-cycle-to-recession margin gap.
• Skin Health & Beauty segment growth < 0.0 (2 consecutive prints). Beauty is the swing segment tied to China and travel retail. Two quarters of outright decline would remove the premium-innovation optionality that supports the Growth path.
• Net-debt / EBITDA > 3.5 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)
• Trailing free cash flow < 1.6 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $19.43; 52-week range $13.47–$21.85; engine rating HOLD; house target $18.40 (-5%). (source: Alpha Vantage 2026-08-24, 25 August 2026)
• INFERENCE: Triangulated FV $16.06 (-17% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

56.3/100 (confidence band 45.7–67.0), 44th percentile of 858 covered names (as of 2026-08-24). Weighted composite under config ros-1.19.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 56.4 → 56.4 → 56.9 → 56.4 → 56.4 → 56.8 → 56.9 → 56.9.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $17.98.

Flagged for review: internal coherence (authored mass vs Monte Carlo). A flag marks a disagreement worth understanding — it does not imply either side is wrong.

Factor Exposures

Cross-sectional percentiles over 858 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.14, vs QQQ +0.05 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Long Stock. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• no directional edge and options are cheap — options add little; hold the stock
• Direction neutral from the overlay conviction/rating (read-only input).
• IV/RV at the 0th percentile of the cross-section → low vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 62nd percentile of its own month-end history (decile 7). The two measures disagree here — vol is high for this name by its own history while its options are not unusually rich against its realised vol. Where they diverge, the cross-sectional measure is the one acting.
• IV term structure is in contango (longer-dated richer, slope +5.9pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.
• No live-chain Long Stock was priced for this name — shown as the indicated strategy; size against a freshly pulled chain.

IV term structure (contango, slope +5.9pp): 32-DTE 21% · 88-DTE 29% · 389-DTE 27%

No live-chain Long Stock was priced for this name — shown as the indicated approach; size against a fresh chain.

Alternatives: . IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the HOLD equity view. Chain as of 2026-08-24 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 21.0% (moderate regime) · expected move ±5.0% (2026-09-25) · put/call OI 0.37 · ATM Δ 0.51 / Θ -0.01 / ν 0.02. Direction: NEUTRAL (implied return -17.4% to triangulated fair value $16.06).

Covered Call (if held) (Income / neutral) — Short 21 C · 2026-09-25 · premium $0.01 · yield 0.1% · priced from the listed chain (EOD marks)

Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Illustrative — no outcome is implied or guaranteed.

Protective Collar (if held) (Hedge) — Long 17 P / Short 21 C · 2027-02-19 · net $0.88 · floor -13.0% · cap +8.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -7% vs spot
• Monte Carlo median implies -16% vs spot
• DCF fair value implies -25% vs spot — but this is terminal-value sensitive (exit-multiple $14.55 vs Gordon $20.76, 43% apart), so it carries less weight
• Bear case (Structural — Private-Label / Brand Erosion) downside is -61% vs spot
• Net: the valuation anchor itself sits 17.3% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 3% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 7.5% · Σ PV(FCF) $10B + PV(terminal) $26B = EV $36B; − net debt $7.6B → equity $28B ÷ diluted shares $1.93B = $14.55/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $20.76/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 17% vs WACC 7.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $7.90 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (6.0); Revenue CAGR ±3pp (5.0); Terminal × ±15% (4.0); WACC ±1pp (2.0); Capex intensity ±15% (1.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 7.5%, terminal multiple 14×, FY+5 revenue $18B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.